Phase II study of MEK inhibitor trametinib alone and in combination with AKT inhibitor GSK2141795/uprosertib in patients with metastatic triple negative breast cancerVishnu Prasath, Bhuvaneswari Ramaswamy, Robert Wesolowski et al.|Breast Cancer Research and Treatment|2024Cited by 12